*6.6.3 Treatment and prognosis*

LPL is an incurable progressive disease, however the tumor growth can be controlled with low doses of chemotherapy and immunotherapy with anti-CD20 antibody. Symptoms caused by the high IgM levels like hyperviscosity and hemolysis can be alleviated by plasmapheresis. The clinical course is typically indolent,

**Figure 6.** *Lymphoplasmacytic lymphoma showing lambda restriction.*

with median survivals of 5–10 years. Transformation to large-cell lymphoma is uncommon [1, 25].
